Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease

Thomas J. Montine; Joseph F. Quinn; Kathleen S. Montine; Jeffrey A. Kaye; John C.S. Breitner

doi:10.3233/jad-2005-8405

Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease

Thomas J. Montine, Joseph F. Quinn, Kathleen S. Montine, Jeffrey A. Kaye, John C.S. Breitner

Neurology

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Dementia from Alzheimer's disease (AD) represents a significant and growing public health burden and presents a clear therapeutic imperative. Key to success in this undertaking will be biomarkers for the objective assessment of disease progression and response to therapeutics. Oxidative damage is one facet of AD pathogenesis for which there are experimentally validated quantitative in vivo biomarkers, the F₂-isoprostanes (IsoPs). While plasma- or urine-based assays are desirable, consistent and reproducible cross-sectional data for increased F₂-IsoPs in AD and mild cognitive impairment have been obtained only for CSF. In addition, measurement of CSF F₂-IsoPs can increase the accuracy of laboratory-based classification of geriatric dementias, and have been used to assess objectively the response to anti-oxidant interventions in AD.

Original language	English (US)
Pages (from-to)	359-367
Number of pages	9
Journal	Journal of Alzheimer's Disease
Volume	8
Issue number	4
DOIs	https://doi.org/10.3233/jad-2005-8405
State	Published - 2005

Keywords

Alzheimer's disease
Biomarkers
F2-isoprostanes
Oxidative stress

ASJC Scopus subject areas

General Neuroscience
Clinical Psychology
Geriatrics and Gerontology
Psychiatry and Mental health

Access to Document

10.3233/jad-2005-8405

Cite this

@article{f49ea4329c0848ed95a983c0a0f33f3f,

title = "Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease",

abstract = "Dementia from Alzheimer's disease (AD) represents a significant and growing public health burden and presents a clear therapeutic imperative. Key to success in this undertaking will be biomarkers for the objective assessment of disease progression and response to therapeutics. Oxidative damage is one facet of AD pathogenesis for which there are experimentally validated quantitative in vivo biomarkers, the F2-isoprostanes (IsoPs). While plasma- or urine-based assays are desirable, consistent and reproducible cross-sectional data for increased F2-IsoPs in AD and mild cognitive impairment have been obtained only for CSF. In addition, measurement of CSF F2-IsoPs can increase the accuracy of laboratory-based classification of geriatric dementias, and have been used to assess objectively the response to anti-oxidant interventions in AD.",

keywords = "Alzheimer's disease, Biomarkers, F2-isoprostanes, Oxidative stress",

author = "Montine, {Thomas J.} and Quinn, {Joseph F.} and Montine, {Kathleen S.} and Kaye, {Jeffrey A.} and Breitner, {John C.S.}",

year = "2005",

doi = "10.3233/jad-2005-8405",

language = "English (US)",

volume = "8",

pages = "359--367",

journal = "Journal of Alzheimer's Disease",

issn = "1387-2877",

publisher = "IOS Press",

number = "4",

}

TY - JOUR

T1 - Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease

AU - Montine, Thomas J.

AU - Quinn, Joseph F.

AU - Montine, Kathleen S.

AU - Kaye, Jeffrey A.

AU - Breitner, John C.S.

PY - 2005

Y1 - 2005

N2 - Dementia from Alzheimer's disease (AD) represents a significant and growing public health burden and presents a clear therapeutic imperative. Key to success in this undertaking will be biomarkers for the objective assessment of disease progression and response to therapeutics. Oxidative damage is one facet of AD pathogenesis for which there are experimentally validated quantitative in vivo biomarkers, the F2-isoprostanes (IsoPs). While plasma- or urine-based assays are desirable, consistent and reproducible cross-sectional data for increased F2-IsoPs in AD and mild cognitive impairment have been obtained only for CSF. In addition, measurement of CSF F2-IsoPs can increase the accuracy of laboratory-based classification of geriatric dementias, and have been used to assess objectively the response to anti-oxidant interventions in AD.

AB - Dementia from Alzheimer's disease (AD) represents a significant and growing public health burden and presents a clear therapeutic imperative. Key to success in this undertaking will be biomarkers for the objective assessment of disease progression and response to therapeutics. Oxidative damage is one facet of AD pathogenesis for which there are experimentally validated quantitative in vivo biomarkers, the F2-isoprostanes (IsoPs). While plasma- or urine-based assays are desirable, consistent and reproducible cross-sectional data for increased F2-IsoPs in AD and mild cognitive impairment have been obtained only for CSF. In addition, measurement of CSF F2-IsoPs can increase the accuracy of laboratory-based classification of geriatric dementias, and have been used to assess objectively the response to anti-oxidant interventions in AD.

KW - Alzheimer's disease

KW - Biomarkers

KW - F2-isoprostanes

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=33645084250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645084250&partnerID=8YFLogxK

U2 - 10.3233/jad-2005-8405

DO - 10.3233/jad-2005-8405

M3 - Article

C2 - 16556967

AN - SCOPUS:33645084250

SN - 1387-2877

VL - 8

SP - 359

EP - 367

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

IS - 4

ER -

Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this